CN101873852A - 治疗视黄醇相关性疾病的方法和化合物 - Google Patents

治疗视黄醇相关性疾病的方法和化合物 Download PDF

Info

Publication number
CN101873852A
CN101873852A CN200880107835A CN200880107835A CN101873852A CN 101873852 A CN101873852 A CN 101873852A CN 200880107835 A CN200880107835 A CN 200880107835A CN 200880107835 A CN200880107835 A CN 200880107835A CN 101873852 A CN101873852 A CN 101873852A
Authority
CN
China
Prior art keywords
alkyl
formula
compound
optionally substituted
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880107835A
Other languages
English (en)
Chinese (zh)
Inventor
内森·L·马塔
金·B·潘
塔姆·V·布伊
穆斯塔法·哈达赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirion Therapeutics Inc
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Publication of CN101873852A publication Critical patent/CN101873852A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN200880107835A 2007-09-27 2008-09-16 治疗视黄醇相关性疾病的方法和化合物 Pending CN101873852A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97576507P 2007-09-27 2007-09-27
US60/975,765 2007-09-27
US98132207P 2007-10-19 2007-10-19
US60/981,322 2007-10-19
PCT/US2008/076499 WO2009042444A2 (en) 2007-09-27 2008-09-16 Methods and compounds for treating retinol-related diseases

Publications (1)

Publication Number Publication Date
CN101873852A true CN101873852A (zh) 2010-10-27

Family

ID=40512081

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880107835A Pending CN101873852A (zh) 2007-09-27 2008-09-16 治疗视黄醇相关性疾病的方法和化合物

Country Status (8)

Country Link
EP (1) EP2205234A4 (enExample)
JP (1) JP2010540541A (enExample)
KR (1) KR20100097098A (enExample)
CN (1) CN101873852A (enExample)
AU (1) AU2008305303A1 (enExample)
CA (1) CA2699773A1 (enExample)
IL (1) IL204728A0 (enExample)
WO (1) WO2009042444A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
JP5706337B2 (ja) * 2009-04-16 2015-04-22 武田薬品工業株式会社 （とりわけ）糖尿病の予防または治療に有用なｎ−アシル−ｎ’−フェニルピペラジンの誘導体
WO2012071369A2 (en) * 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
BR112013013522A2 (pt) * 2010-12-02 2019-09-24 Daiichi Sankyo Co Ltd polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
BR112016025356B1 (pt) 2014-04-30 2023-04-18 The Trustees Of Columbia University In The City Of New York Compostos de 4-fenilpiperidinas substituídas, composições e seus usos
RS61504B1 (sr) 2014-10-24 2021-03-31 Takeda Pharmaceuticals Co Jedinjenja heteroarila za lečenje oftalmičkih bolesti
JP6646586B2 (ja) * 2014-10-24 2020-02-14 武田薬品工業株式会社 複素環化合物
WO2021222654A1 (en) * 2020-04-29 2021-11-04 Saliogen Therapeutics, Inc. Compositions and methods for treatment of inherited macular degeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2526534A (en) * 1948-07-03 1950-10-17 Dow Chemical Co Di-(aryloxy)-methanes
US4255152A (en) * 1978-09-05 1981-03-10 Ciba-Geigy Corporation Process for the dyeing of hydrophobic fibres
JPS577480A (en) * 1980-06-16 1982-01-14 Sankyo Co Ltd 4-alkoxy-6-phenoxymethyl-2-pyrone derivative
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US20090155903A1 (en) * 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
WO2005116010A1 (en) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Also Published As

Publication number Publication date
CA2699773A1 (en) 2009-04-02
AU2008305303A1 (en) 2009-04-02
WO2009042444A3 (en) 2009-05-14
KR20100097098A (ko) 2010-09-02
WO2009042444A2 (en) 2009-04-02
IL204728A0 (en) 2010-11-30
EP2205234A2 (en) 2010-07-14
JP2010540541A (ja) 2010-12-24
EP2205234A4 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
CN101873852A (zh) 治疗视黄醇相关性疾病的方法和化合物
US7973079B2 (en) Methods and compounds for treating retinol-related diseases
TWI396532B (zh) 用視黃基衍生物治療眼疾之方法及組合物
KR102073578B1 (ko) App 특이적 bace 억제제(asbi) 및 이의 용도
JP2022066315A (ja) 注意欠陥障害の処置のための方法および組成物
US11427540B2 (en) Formulations of T-type calcium channel modulators and methods of use thereof
JP5841333B2 (ja) 安定化されたカリスバメートの小児用懸濁液
CN104995176B (zh) 调节bace所介导的app加工的乙内酰脲
CA3083347A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN101252924A (zh) 通过血清视黄醇、血清视黄醇结合蛋白(rbp)和/或血清视黄醇-rbp调节治疗眼部疾病的方法和组合物
JP2021152032A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
CN103191129A (zh) 治疗眼睛病症的脂氧化物类化合物
TW201038544A (en) Anti-neurodegenerative diseases agents
JP2013545792A (ja) 眼疾患の処置および防止方法
US20170296523A1 (en) Pharmaceutical Compositions Comprising Alpelisib
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
CN103153309A (zh) 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
WO2012078525A2 (en) Compositions and methods for treating ophthalmic conditions
CN108245510B (zh) 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
US20190201376A1 (en) Method for Treating or Preventing Fatty Acid Binding Protein 3 Induced B-amyloid Aggregation Diseases
CN102988331B (zh) 2-巯基-3-丁醇用于制备抗晶状体混浊产品的用途
GB2597282A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP2320912B1 (en) Treatment of retinal degeneration
CN119587551A (zh) 厄洛替尼在制备促进视网膜色素上皮细胞移植后的整合药物中的应用
US20080033045A1 (en) Treatment of psychiatric disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101027